Omiya Toshinobu, Tanaka Sakae
Nihon Rinsho. 2015 Oct;73(10):1690-5.
RANKL (receptor activator of nuclear factor-κB ligand) critically regulates the differentiation, activation, and survival of the osteoclast, and the hyperactivation of the RANKL-RANK signaling pathway leads to osteoporosis. Denosumab is a complete human monoclonal antibody against human RANKL, and suppresses bone resorption by inhibiting the interaction between RANKL and RANK. Accumulating evidence has demonstrated the clinical usefulness of denosumab on postmenopausal osteoporosis. Although the effectiveness of denosumab on disease activity of rheumatoid arthritis has not been clarified yet, previous studies reported that denosumab significantly increased the bone density of lumbar spine and proximal femur of rheumatoid arthritis patients.
核因子κB受体活化因子配体（RANKL）对破骨细胞的分化、活化及存活起着关键调节作用，而RANKL-RANK信号通路的过度激活会导致骨质疏松症。地诺单抗是一种完全人源化的抗人RANKL单克隆抗体，通过抑制RANKL与RANK之间的相互作用来抑制骨吸收。越来越多的证据表明地诺单抗在绝经后骨质疏松症治疗中的临床应用价值。尽管地诺单抗对类风湿关节炎疾病活动的有效性尚未明确，但先前的研究报道地诺单抗可显著提高类风湿关节炎患者腰椎和股骨近端的骨密度。
